secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2023-05-01T23:59:59+00:00
Accession:  0001104659-23-053387
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Priveterra amends AEON Biopharma merger: lower cash condition, extended termination, new sponsor vesting terms
--------------------------------------------------------------------------------

- Minimum cash condition reduced from $45M to $40M; expense cap increased to $10.3M.
- 70% of founder shares (4.83M) become contingent, vesting based on $5.00 avg price or forfeited.
- Termination date extended to July 21, 2023; board set at 5 directors (2 AEON, 1 SPAC, 2 independent).
- Promissory note of up to $1M issued to sponsor, non-interest bearing, payable at business combination.
- Outstanding AEON RSUs and options converted to combined company equity with adjustments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000110465923053387/0001104659-23-053387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000110465923053387/tm2314221d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-053387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer